A previous analysis showed that GAPDHS mRNA expression is enhanced in some melanoma cell lines compared with controls (Sevostyanova et al., 2012), and it has recently been correlated with an adverse clinical outcome in stage III–IV melanoma (Falkenius et al., 2013). This evidence concerns the gene GAPDHS and melanoma.